Thymosin α1

Thymalfasin; Tα1; Ac-thymosin α1

Identity

Sequence

Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN

Three-letter

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

Length

28 residues

Modifications

N-terminal acetyl

Formula

C129H215N33O55

Average mass

3108.3 Da

CAS

62304-98-7

Specifications (per released lot)

Purity

≥ 98 % by RP-HPLC, 220 nm

Identity

ESI-MS; observed mass within 0.1 % of calculated

Form

White to off-white lyophilized powder

Counter-ion

Trifluoroacetate; acetate on request

Net peptide content

Reported per lot (typically 70–90 % of gross mass; the balance is counter-ion and water)

Vial sizes

5 mg · 10 mg · 25 mg net peptide; bulk on quotation

Storage

−20 °C, desiccated, protected from light. Ships at ambient temperature.

Documents

Lot certificate of analysis (COA library); safety data sheet in WHMIS 2015 format, enclosed with every shipment

Research context

28-residue N-acetylated peptide derived from prothymosin α. Used in immunomodulation, T-cell maturation and dendritic-cell studies. Marketed as a drug in several countries outside North America; not authorized in Canada or the United States.

Literature context is provided to help laboratories identify the reagent. It is not a claim about effects in people and does not describe any use outside in-vitro or approved animal research.